5 Min Read FRANKFURT/PARIS (Reuters) - Europe’s medicines watchdog concluded on Thursday that AstraZeneca’s coronavirus vaccine still far outweighed any risks after investigating reports of rare blood clotting disorders but said it would add a warning to the product leaflet. FILE PHOTO: AstraZeneca logo is reflected in a drop on a syringe needle in this illustration photo taken March 16, 2021. Picture taken March 16, 2021. REUTERS/Dado Ruvic/Illustration/File Photo “A causal link with the vaccine is not proven, but is possible and deserves further analysis,” the European Medicines Agency (EMA) said. The World Health Organization has previously also said there was no proven link and that the benefits far outweighed any risks. At least 13 EU member states including Germany, France and Italy have suspended use of the shot pending the outcome of EMA’s probe.